Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A
Antonietta Franco1, Xiawei Dang1,2, Emily K Walton1
1Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States.
Elife
|October 19, 2020
Summary
A new drug, MiM111, shows promise for treating Charcot-Marie-Tooth disease type 2A (CMT2A) by activating healthy mitofusins, reversing mitochondrial issues, and improving nerve function in preclinical models.
Area of Science:
- Neuroscience
- Genetics
- Mitochondrial Biology
Background:
- Charcot-Marie-Tooth disease type 2A (CMT2A) is a debilitating childhood peripheral neuropathy.
- It stems from mutations in the mitofusin (MFN) 2 gene, crucial for mitochondrial fusion.
- Current treatments for CMT2A are lacking.
Purpose of the Study:
- To investigate pharmacological activation of mitofusins as a therapeutic strategy for CMT2A.
- To assess the efficacy of the small molecule MiM111 in preclinical models of CMT2A.
Main Methods:
- Reprogrammed human patient motor neurons were used to test MFN2 mutant effects.
- A mouse model expressing a human MFN2 mutation (T105M) was developed.
- Intermittent administration of MiM111 was employed in the mouse model.
Main Results:
- MiM111 reversed mitochondrial stasis and fragmentation in human neurons.
- In mice, MiM111 normalized neuromuscular function and reversed muscle atrophy.
- The drug enhanced axon regrowth by improving mitochondrial transport and synaptic localization.
Conclusions:
- Pharmacological activation of mitofusins is a viable therapeutic approach for CMT2A.
- MiM111 demonstrates significant preclinical efficacy, representing a potential first-in-class treatment for CMT2A.
- Enhanced mitochondrial dynamics and transport are key mechanisms underlying MiM111's therapeutic effects.
